Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.42 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.42 |
| ▸ | USP28 | Q96RU2 | 2/20 | 0.42 |
| ▸ | USP25 | Q9UHP3 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3299945 | 0.91 | ADORA2A (0.55) | ADORA2AADORA1CHRM4ALDH1A1 | |
| SCHEMBL13407610 | 0.83 | LIMK1 (0.49) | ADORA2AADORA1CHRM4NAMPTHDAC2 | |
| SCHEMBL3302089 | 0.82 | CHRM4 (0.46) | ADORA2AADORA1CHRM4NAMPTHDAC2 | |
| SCHEMBL13389221 | 0.80 | LIMK1 (0.46) | ADORA2AADORA1CHRM4NAMPTHDAC2 | |
| SCHEMBL3301936 | 0.80 | ADORA2A (0.54) | ADORA2AADORA1LIMK1LIMK2ALDH1A1 | |
| SCHEMBL13389260 | 0.79 | ADORA2A (0.59) | ADORA2AADORA1CHRM4RAB9A | |
| SCHEMBL13389206 | 0.77 | ADORA2A (0.52) | ADORA2AADORA1CHRM4ALDH1A1RAB9A | |
| Hydrochloric Acid SCHEMBL3295775 | 0.76 | ADORA2A (0.51) | ADORA2AADORA1CHRM4ALDH1A1RAB9A | |
| SCHEMBL3338496 | 0.75 | ADORA2A (0.49) | ADORA2AADORA1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13407611 | 0.74 | ADORA2A (0.49) | ADORA2AADORA1CHRM4POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010045008-A1 | AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | WO | disclosed |
| US-20100093714-A1 | AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093714-A1 | AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093714-A1 | AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093714-A1 | AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA1 4/4885CHRM4 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.